• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC | Inspections
 


New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
 
Trade NamePATHWAY HER-2/NEU (CLONE CD11) PRIMARY ANTIBODY
Classification Namesystem, test, her-2/neu, ihc
Generic Namemouse monoclonal antibody for aid in the detection of c-eerbb-2 antigen in histological tissue section
ApplicantVENTANA MEDICAL SYSTEMS, INC.
PMA NumberP990081
Supplement NumberS002
Date Received09/07/2005
Decision Date10/21/2005
Product Code
MVC[ Registered Establishments with MVC ]
Advisory Committee Immunology
Supplement Typereal-time process
Supplement Reason labeling change - instructions
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Approval of labeling changes for the pathway her-2/neu (clone cd11) in the "intended use" section, addition of an "optional equipment not provided" section and changes to the "principles and procedures" section to reflect the addition of tripath imaging vias instrument to be used in conjunction with the ventana pathway her 2 assay as an optional accessory. The device, as modified, will be marketed under the same trade name patyhway her-2/neu (clone cd11) and is indicated: ventana medical systems, inc. 's (ventana) pathway her 2 (clone cd11) is a mouse monoclonal antibody intended for laboratory use for the semi-quantitative detection of c-erbb2- antigen in sections of formalin fixed, paraffin embedded normal and neoplastic tissue on a ventana automated immunohistochem-istry slide staining device. It is indicated as an aid in the assessment of breast cancer patients for whom herceptin treatment is considered. Note: all of the patients in the herceptin clinical trials were selected using a clinical trial assay. None of the patients in those trials were selected using pathway her 2. The pathway her 2 was compared to the dako herceptest on an independent sample and found to provide acceptably concordant results. The actual correlation of pathway her 2 to clinical outcome has not been established. The ventana image analysis system (vias) is adjunctive optional computer-assisted image analysis system functionally connected to an interactive microscope. It is intended for use as an aid to the pathologist in the detection classification and counting of cells of interest based on market intensity, size and shape using appropriate controls to assure the validity of the vias scores.
-
-